Firebrick Pharma Achieves Dual Patent Approvals in Canada and New Zealand Amid 43% Adjusted Sales Growth

Expansion of Intellectual Property and Patent Strategy Across Multiple Jurisdictions

On 13 May 2026, Firebrick Pharma announced the acceptance of its pandemic use patent titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes" in Canada, expiring in 2040. This patent is also granted or accepted in the United States, Europe, Australia, and the Philippines, with pending applications in other countries, reinforcing the company’s strategic protection of its core technology in major markets.

Subsequently, on 3 June 2026, the company confirmed the grant of its "Improved Virucidal Formulations" patent in New Zealand, expiring in 2041. This patent has also been approved in Australia and South Africa, with pending status in additional international territories. Firebrick’s phased patent approval approach supports streamlined market entry and regulatory compliance aligned with patent protection timelines.

FY26 Sales Growth and Market Penetration Developments

Firebrick reported $66,000 in cash sales for the June 2026 quarter, culminating in $227,000 for FY26. While this initially appears lower than FY25’s $305,000, the prior year included a one-off $146,000 pipeline receipt disclosed on 23 July 2025. Excluding this, FY25 sales adjust to $159,000, indicating a 43 percent year-on-year growth in FY26.

This growth is notable for a pharmaceutical company in early commercialization stages. Firebrick has launched Nasodine Nasal Spray (0.5% povidone-iodine) in the United States, Singapore, and Fiji, with Nasodine Throat Spray available in Singapore and Fiji. The company plans up to four Nasodine products and aims to expand sales into 10 markets within three years, signaling early validation of its product strategy despite modest absolute revenues.

Analysis of Quarterly Cash Burn and Operating Expenses

Cash operating expenses rose slightly to $839,000 in the June 2026 quarter, a 2 percent increase from $821,000 in March. The rise was attributed to prepayments for projects expected in the September quarter and other one-off costs, which are not anticipated to recur.

After accounting for $66,000 in sales and other receipts, net cash burn was $768,000 for the quarter. FY26 operating expenses totaled $3,078,000, consistent with FY25’s $3,068,000, despite accelerated sales growth. The full-year net cash burn was $2,603,000, averaging $650,000 per quarter, providing investors with a baseline for assessing the company’s cash runway and funding needs.

Operating Expense Breakdown and Cost Management Focus

According to the Appendix 4C cash flow report, research and development expenses were $142,000 for the quarter and $419,000 for FY26. Product manufacturing and operational costs totaled $39,000 quarterly and $362,000 annually. Advertising and marketing expenses, critical for commercialisation, were $123,000 in the quarter and $442,000 for the year.

Staff costs, the largest expense category, amounted to $348,000 in the quarter and $1,063,000 for FY26. Administration and corporate expenses were $166,000 quarterly and $709,000 annually. Leased assets costs were $21,000 for the quarter and $84,000 yearly. Payments to related parties, including executive and non-executive director fees, totaled $320,000 in the quarter. Labor expenses represent about 35 percent of total operating costs, typical for early-stage pharmaceutical firms focused on development and regulatory processes.

Cash Position and Balance Sheet Status as of 30 June 2026

Firebrick held $1,322,000 in cash and equivalents at quarter-end, consisting entirely of bank balances with no call deposits or overdrafts. This position reflects the opening balance plus equity capital raises, offset by operational cash burn. Net cash from financing activities was $1,299,000 in the quarter and $2,942,000 for FY26, primarily from equity issuances totaling $1,405,000 quarterly and $3,052,000 annually.

Equity issuance transaction costs were $110,000 for the quarter and $126,000 for the year. Option exercise proceeds were $4,000 quarterly and $16,000 annually. No dividends were paid, and the company reported no borrowings or financing costs. With an average quarterly cash burn of $768,000—elevated by prepayments—the current cash runway is approximately 1.7 quarters, highlighting the importance of near-term capital management and potential equity raises.

Government R&D Tax Incentives and Non-Recurring Income Sources

During FY26, Firebrick received $251,000 from government grants and the 2025 R&D tax incentive, partially offsetting cash burn and reflecting eligibility for innovation support. No such receipts were recorded in the June quarter, indicating the prior period receipt timing.

Additional miscellaneous receipts were reported but not detailed. Interest income was $4,000 for the quarter and $9,000 for FY26. GST payments resulted in a net outflow of $11,000 annually, with a $1,000 net inflow in the quarter. These minor items contribute to net cash flow, though primary income drivers remain product sales and equity funding.

Strategic Product Pipeline and Market Expansion Plans Through 2029

Firebrick’s Nasodine product line currently includes Nasodine Nasal Spray (0.5% povidone-iodine) and Nasodine Throat Spray, with plans for up to four products total. This pipeline expansion reflects confidence in the povidone-iodine platform and market demand for topical viral prevention and treatment.

Current markets include the United States, Singapore, and Fiji for Nasodine Nasal Spray, with Nasodine Throat Spray available in Singapore and Fiji. Nasodine Nasal Spray recently gained marketing approval in Indonesia. The company is pursuing regulatory approvals in the Philippines and other regions, supporting a diversified geographic rollout strategy to mitigate concentration risk and capitalize on povidone-iodine’s virucidal properties amid pandemic preparedness and endemic viral prevention.

Regulatory Progress and Approval Timelines for Additional Markets

Patent grants across Canada, New Zealand, Australia, the United States, Europe, South Africa, and the Philippines demonstrate Firebrick’s regulatory engagement in key pharmaceutical markets. Several patents remain pending internationally, indicating ongoing prosecution and future milestones.

Recent approvals in Indonesia and active pursuit in the Philippines highlight progress in Southeast Asia, a high-growth healthcare region. Regulatory timelines vary by country, influenced by local requirements, manufacturing compliance, and clinical data. Investors should monitor updates on approvals in the Philippines and other markets as potential near-term value drivers.

Cash Flow Summary and Equity Capital Raising in FY26

Firebrick’s net cash increased by $791,000 in the June quarter and $983,000 for FY26, driven mainly by equity capital raises offsetting operational cash burn. The opening cash balance on 1 July 2025 was approximately $339,000, calculated from the closing balance minus net increase.

Equity proceeds totaled $1,405,000 for the quarter and $3,052,000 for the year, net of transaction costs of $110,000 and $126,000 respectively, reflecting substantial shareholder investment supporting operations and commercialization.

No capital expenditures on property, plant, equipment, or intellectual property were reported, indicating reliance on outsourced manufacturing and services. This capital-efficient model suits an early-stage pharmaceutical company focused on product development and regulatory compliance rather than infrastructure investment.

Povidone-Iodine Market Overview and Firebrick’s Competitive Position

Povidone-iodine has a long-standing safety and efficacy record as a topical antiseptic with broad-spectrum virucidal, bactericidal, and fungicidal activity. Available over-the-counter or by prescription globally, Firebrick’s novel formulations and patent portfolio—including pandemic use, improved virucidal formulations, and nasal and throat applications—allow it to capture value through innovation and targeted market positioning.

The regulatory environment for povidone-iodine products is well-established, though competition from generic manufacturers is intense. Firebrick’s differentiation lies in branded Nasodine formulations, optimized delivery systems, and patent-backed claims, focusing on viral prevention via nasal and throat routes. This niche is especially relevant amid heightened pandemic preparedness and endemic respiratory virus concerns among consumers and healthcare providers.